September 24th 2024
During a Case-Based Roundtable® event, Michael R. Bishop, MD, moderated a discussion on monitoring and treatment of chronic graft-vs-host disease.
September 24th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Ponatinib/Blinatumomab Displays Efficacy as a Chemo-Free, HSCT-Sparing Option in Ph+ ALL
September 28th 2022In an interview before the conference, Fadi G. Haddad, MD, discussed the updated results from the combination of blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Read More
Guidelines Needed for Monitoring Pulmonary Complications After Pediatric HSCT
August 12th 2022Several priority areas need to be examined in future research to improve the quality of clinical guidelines to address when and how to monitor pediatric hematopoietic stem cell transplant survivors.
Read More
Omidubicel Developer Seeks FDA Approval to Treat Blood Cancers in Need of Transplantation
June 3rd 2022Within 60 days, the FDA will make a decision on whether to accept the biologics license application for omidubicel as treatment for patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.
Read More
Stem Cell Transplant Holds its Position as Upfront Treatment for Hematologic Malignancies
May 10th 2022In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed the evolving role of stem cell transplant in hematologic malignancies as CAR T-cell therapies begin to reshape treatment landscapes.
Read More
Ruxolitinib Adverse Event Data and Strategies for Managing Side Effects
April 7th 2022Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.
Watch